KALA

KALA BIO, Inc.

5.49 USD
+0.09 (+1.67%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

KALA BIO, Inc. stock is down -15.54% since 30 days ago. The next earnings date is Aug 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 June’s closed higher than May.

About KALA BIO, Inc.

Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.